Additional file 1: of Mobile Exergaming for Health—Effects of a serious game application for smartphones on physical activity and exercise adherence in type 2 diabetes mellitus—study protocol for a randomized controlled trial

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 checklist. (DOC 121 kb

Patient characteristics for included and excluded cytomegalovirus (CMV) disease cases.

<p><i>Abbreviations:</i> IQR, interquartile range; CMV, cytomegalovirus; HIV, human immunodeficiency virus; cART, combination antiretroviral therapy; IRIS, immune reconstitution inflammatory syndrome.</p>1<p>Cases diagnosed with both “CMV not liver, spleen or lymph nodes” and “CMV retinitis” are counted as the former (n = 2 and n = 20 for included and excluded CMV disease cases respectively).</p>2<p>These statistics represent the clinical stage a patient had prior to the index date.</p>3<p>Based on the date of (for included and excluded CMV disease cases respectively): a first documented positive test (49%, 39%), a first reported positive test (33%, 38%) or the cohort registration visit (18%, 22%).</p>4<p>Herpes simplex disease, mucocutan. Herpes simplex ulceration, herpes zoster multidermatomal or relapse, disseminated toxoplasmosis, toxoplasmosis retinitis or toxoplasmosis of the brain within ±90 days of the index date.</p

Associations between cytomegalovirus (CMV) disease and mannan-binding lectin (MBL)/ficolin levels.

<p><i>Abbreviations:</i> MBL, mannan-binding lectin; CI, confidence interval.</p>1<p>Per 10 years increase.</p><p>A) Univariable conditional logistic regression models for MBL, H-ficolin (3), L-ficolin (2) and M-ficolin (1). B) Multivariable conditional logistic regression model for MBL adjusted for the effects of potentially confounding risk factors for CMV disease based on 89 case-control pairs without missing data. C) Conditional logistic regression model for MBL, investigating its relationship with CD4 T-cell count. D) Conditional logistic regression model with a linear spline for MBL.</p

Density plots of the distribution of mannan-binding lectin (MBL), H-ficolin (3), L-ficolin (2), and M-ficolin (1) levels among cases (solid line) and controls (dashed line), with marker levels given in ng/mL.

<p>Density plots of the distribution of mannan-binding lectin (MBL), H-ficolin (3), L-ficolin (2), and M-ficolin (1) levels among cases (solid line) and controls (dashed line), with marker levels given in ng/mL.</p

Duration of antibiotic treatment.

<p>Box plots of the distribution of the duration of antibiotic (AB) treatment (in days) for children and adolescents with lower respiratory tract infection (LRTI) in the procalcitonin (PCT) and control group.</p

Trial profile.

<p>Trial profile.</p

Patient baseline characteristics.

<p>Abbreviations: PCT, procalcitonin; IQR, interquartile range; CRP, C-reactive protein; Non-CAP, non-community-acquired pneumonia; LRTI, lower respiratory tract infection. * N in this column indicate the number of individuals with information on a particular variable.</p

Subgroup analyses.

<p>Abbreviations: PCT, procalcitonin; CI, confidence interval; Non-CAP, non-community-acquired pneumonia; LRTI, lower respiratory tract infection. * Number of individuals with available data for a given endpoint.</p

Impairment of daily activities.

<p>Impairment of daily activities attributable to lower respiratory tract infection (LRTI) over time in 267 children and adolescents who returned diaries in the procalcitonin (PCT) and control group. The smooth curves are local averages calculated using the default loess smoother in R.</p